文献速递其他结缔组织病

益生菌治疗系统性硬化症相关胃肠道疾病的双盲随机安慰剂对照试验

A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease.
PubMed 文献 · Semin Arthritis Rheum · 2019-05-23

结果显示60天时总体胃肠道评分无显著组间差异,但120天时益生菌组胃食管反流症状显著改善,且粪便菌群α多样性增加,不良事件轻微。

要点

  • 60天时总体胃肠道评分无显著改善(安慰剂0.14±0.06 vs 益生菌0.13±0.07,p=0.85)。
  • 120天时益生菌组胃食管反流评分显著改善(-0.22±0.05 vs 安慰剂-益生菌组0.05±0.07,p=0.004)。
  • 益生菌组粪便菌群α多样性较安慰剂-益生菌组增加,不良事件轻微且两组相似。

核心结论

  • 60天益生菌治疗未显著改善系统性硬化症患者总体胃肠道症状,但120天时胃食管反流症状显著改善。
  • 多菌株益生菌在系统性硬化症患者中安全性良好。

研究设计与样本

  • 随机1:1接受60天高剂量多菌株益生菌(Vivomixx® 1800亿单位/天)或安慰剂,随后两组均再接受60天益生菌。
  • 在意向性治疗人群中评估60天(主要终点T1)和120天(次要终点T2)胃肠道评分变化,并在三个时间点进行粪便16S下一代测序。

主要发现

  • T1时两组总体胃肠道评分无显著改善(安慰剂0.14±0.06 vs 益生菌0.13±0.07,p=0.85),各子域亦无显著差异。
  • T2时总体胃肠道评分无显著改善(安慰剂-益生菌-0.05±0.06 vs 益生菌-益生菌-0.18±0.07,p=0.14)。
  • T2时益生菌组胃食管反流评分显著改善(-0.22±0.05 vs 安慰剂-益生菌组0.05±0.07,p=0.004)。
  • 益生菌组粪便菌群α多样性较安慰剂-益生菌组增加。
  • 不良事件轻微,两组发生不良事件和严重不良事件的比例相似。

关键数值与推荐

  • 入组标准为系统性硬化症-specific胃肠道问卷总分≥0.1。
  • 主要终点为60天时胃肠道评分变化,次要终点为120天时变化。

临床怎么用

  • 对于系统性硬化症相关胃食管反流症状,可考虑使用多菌株益生菌治疗120天以改善反流。
  • 益生菌治疗60天对总体胃肠道症状改善不明确,需权衡预期获益。
  • 多菌株益生菌在系统性硬化症患者中安全性良好,不良事件轻微。

局限性

  • 研究未报告安慰剂-益生菌组在T2时胃食管反流评分变化的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Assess whether treatment with probiotics improve gastrointestinal symptoms in patients with systemic sclerosis (SSc). METHODS: In this double-blind randomized placebo-controlled parallel-group phase II trial, SSc subjects with total score ≥ 0.1 on a validated SSc-specific gastrointestinal tract (GIT) questionnaire were randomized (1:1) to receive 60 days of high dose multi-strain probiotics (Vivomixx® 1800 billion units/day) or identical placebo, followed by an additional 60 days of probiotics in both groups. Between group differences in GIT score change were assessed after 60 days (primary outcome, time-point T1) and 120 days (secondary outcome, time-point, T2) by an intention-to-treat approach. Stool samples at three time-points were subjected to 16S next generation sequencing. RESULTS: Forty subjects were randomized to placebo-probiotics (n = 21) or probiotics-probiotics (n = 19). At T1, no significant improvement was observed between the two groups, reported as mean ± SE for total GIT score (placebo 0.14 ± 0.06 versus probiotics 0.13 ± 0.07; p = 0.85) or its subdomains. At T2, whilst there was no significant improvement in total GIT score (placebo-probiotics -0.05±0.06; probiotics-probiotics -0.18 ± 0.07; p = 0.14), there was significant improvement of GIT-reflux in the probiotic group (-0.22 ± 0.05 versus placebo-probiotics 0.05 ± 0.07; p = 0.004). Subjects on probiotics exhibited increasing stool microbiota alpha diversity compared to the placebo-probiotics group. Adverse events (AEs) were mild, with similar proportion of subjects with AEs and serious AEs in both groups. CONCLUSION: Whilst there was no clear improvement in overall GI symptoms after 60 days, we observed significantly improved GI reflux after 120 days of probiotics. The trial confirmed safety of multi-strain probiotics in SSc patients. TRIAL REGISTRATION: Clinicaltrials.gov; NCT01804959.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Low AHL, Teng GG, Pettersson S, et al. A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease. Semin Arthritis Rheum. 2019. PMID: 31208714. doi:10.1016/j.semarthrit.2019.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。